A lot of good questions from individual investors, clearly some from this board. Congratulations to all of them who participated.
I was struck by Varney's quick and succinct answer to Neuroinv's question about MRK and the schizophrenia and depression rights. My reading is that CORX is working diligently to get those rights back AND to gain access to the data generated by the Organon studies. You couple Varney's response with his allusion to PFE and its Ampakine studies in cognitive enhancement and I don't think you have to be a genius to figure out that Varney is anxious to look at the possibilities of the low-impacts in enhancing cognitive functioning in schizo, depression and even AD.
On the high-impacts, I was interested to hear Varney state that he was looking for a "discovery program partnership" with a company that already had (pre-clinical? or clinical?) experience with Ampakines. Maybe Neuroinv can gives us some ideas about which companies Varney might be referring to.
Three months was the guideline for starting to enroll in the Phase IIa with CX1739 in ADHD. Vareny said the study would be better powered than the study with CX717.
SA enrollment expected to be completed by end of summer.
Potential early milestone from Biovail on intravenous form of CX717.
I wonder if Neuroinv can comment on Varney's reference to Cypress' SA studies. I wasn't quite sure of Varney's point there.
Bladerunner
Market Data 
Markets 
AI
